Guggenheim Upgrades Eli Lilly (LLY) Price Target Ahead of Q2 Earnings
Guggenheim increases Eli Lilly (LLY) price target to $1,273, projecting Q2 revenue above consensus. Retatrutide success probability raised to 85%. The post Guggenheim Upgrades Eli Lilly (LLY) Price…
Read the full articleYou might also wanna read
Guggenheim Ups Eli Lilly (LLY) Price Target to $1,273 on Pipeline Strength
Guggenheim raises Eli Lilly (LLY) price target to $1,273, citing strong tirzepatide growth and retatrutide pipeline potential. Q2 earnings e
Eli Lilly’s $400 Billion Surge Is Reshaping Big Pharma
Roughly $400 billion. That is how much market value Eli Lilly (NYSE:LLY) has added over the past year, with shares climbing from $773.86 on
Eli Lilly (NYSE:LLY) Shares Rise After Atai Partnership Could Unlock $1 Billion in Milestones
NEW YORK, July 16, 2026, 5:08 p.m. EDT – Shares of Eli Lilly (NYSE:LLY) edged higher on Thursday after the drugmaker announced a deal with A
Eli Lilly Revenue Surges 55.5% on Mounjaro Sales, But Stock Lags Amid Pricing Pressures
Eli Lilly reported strong revenue growth and raised full-year guidance, but pricing pressure and insider selling have limited the stock’s ne
briefly.co·27d agoLLY Maintained by Guggenheim -- Price Target Lowered to $1273
Related Stocks: LLY
Is Eli Lilly and Co (LLY) a Bargain After 2.3% Drop? GF Value Says Undervalued
Related Stocks: LLY
Comments
Sign in to join the conversation.
No comments yet. Be the first.